These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 35133654)

  • 21. Familial Eruptive Pseudoangiomatosis: 2 Recurring Cases.
    García-Harana C; Del Boz-González J; Padilla-España L; Rodriguez-Lobalzo S; de Troya-Martín M
    Actas Dermosifiliogr (Engl Ed); 2020 Jan; 111(1):73-75. PubMed ID: 31653325
    [No Abstract]   [Full Text] [Related]  

  • 22. Eruptive pseudoangiomatosis associated to cytomegalovirus infection.
    Pitarch G; Torrijos A; García-Escrivá D; Martínez-Menchón T
    Eur J Dermatol; 2007; 17(5):455-6. PubMed ID: 17673403
    [No Abstract]   [Full Text] [Related]  

  • 23. [An outbreak of eruptive pseudoangiomatosis].
    Brouillard C; Guyot Caquelin P; Truchetet F
    Ann Dermatol Venereol; 2012 Oct; 139(10):684-5. PubMed ID: 23122385
    [No Abstract]   [Full Text] [Related]  

  • 24. Eruptive pseudoangiomatosis in a child undergoing chemotherapy for Hodgkin lymphoma.
    Henry M; Savaşan S
    Pediatr Blood Cancer; 2012 Aug; 59(2):342-3. PubMed ID: 22184104
    [No Abstract]   [Full Text] [Related]  

  • 25. [Eruptive pseudoangiomatosis in infant and newborns].
    Guillot B; Chraibi H; Girard C; Dereure O; Lalande M; Bessis D
    Ann Dermatol Venereol; 2005 Dec; 132(12 Pt 1):966-9. PubMed ID: 16446638
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Two cases of eruptive pseudoangiomatosis induced by mosquito bites.
    Oka K; Ohtaki N; Kasai S; Takayama K; Yokozeki H
    J Dermatol; 2012 Mar; 39(3):301-5. PubMed ID: 22211324
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Eruptive pseudoangiomatosis in an adult renal transplant recipient].
    Mazereeuw-Hautier J; Cambon L; Bonafé JL
    Ann Dermatol Venereol; 2001 Jan; 128(1):55-6. PubMed ID: 11226904
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Immunogenicity and safety of a heterologous prime-boost COVID-19 vaccine schedule: ChAdOx1 vaccine Covishield followed by BBV152 Covaxin.
    Kant R; Dwivedi G; Zaman K; Sahay RR; Sapkal G; Kaushal H; Nyayanit DA; Yadav PD; Deshpande G; Singh R; Chaowdhary S; Gupta N; Kumar S; Abraham P; Panda S; Bhargava B
    J Travel Med; 2021 Dec; 28(8):. PubMed ID: 34652440
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Eruptive angiomatosis after SARS-CoV-2 vaccine (Comirnaty, Pfizer).
    Zengarini C; Misciali C; Lazzarotto T; Dika E
    J Eur Acad Dermatol Venereol; 2022 Feb; 36(2):e90-e91. PubMed ID: 34606666
    [No Abstract]   [Full Text] [Related]  

  • 30. Clinicopathologic review of eruptive pseudoangiomatosis in Korean adults: report of 32 cases.
    Kim JE; Kim BJ; Park HJ; Park YM; Park CJ; Cho SH; Kim SY; Kang H
    Int J Dermatol; 2013 Jan; 52(1):41-5. PubMed ID: 23113694
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Eruptive pseudoangiomatosis - cherry angiomas with perilesional halo.
    Chopra D; Sharma A; Kaur S; Singh R
    Indian J Dermatol Venereol Leprol; 2018; 84(4):424-430. PubMed ID: 29327698
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Humoral antibody kinetics with ChAdOx1-nCOV (Covishield™) and BBV-152 (Covaxin™) vaccine among Indian Healthcare workers: A 6-month longitudinal cross-sectional Coronavirus Vaccine-induced antibody titre (COVAT) study.
    Singh AK; Phatak SR; Singh R; Bhattacharjee K; Singh NK; Gupta A; Sharma A
    Diabetes Metab Syndr; 2022 Feb; 16(2):102424. PubMed ID: 35150961
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comment on 'Development of eruptive pseudoangiomatosis following COVID-19 inmunization-apropos of 5 cases': could eruptive pseudoangiomatosis represent a paraviral eruption associated with SARS-CoV-2?
    Moya-Martinez C; Berná-Rico ED; Melian-Olivera A; Moreno-Garcia Del Real C; Fernández-Nieto D
    J Eur Acad Dermatol Venereol; 2022 Feb; 36(2):e95-e97. PubMed ID: 34657329
    [No Abstract]   [Full Text] [Related]  

  • 34. Sub-optimal neutralisation of omicron (B.1.1.529) variant by antibodies induced by vaccine alone or SARS-CoV-2 Infection plus vaccine (hybrid immunity) post 6-months.
    Medigeshi GR; Batra G; Murugesan DR; Thiruvengadam R; Chattopadhyay S; Das B; Gosain M; Ayushi ; Singh J; Anbalagan A; Shaman H; Pargai K; Mehdi F; Das SJ; Kahlon N; Singh S; Kshetrapal P; Wadhwa N; Pandey AK; Bhatnagar S; Garg PK
    EBioMedicine; 2022 Apr; 78():103938. PubMed ID: 35305396
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Annular Eruptive Pseudoangiomatosis and Adenovirus Infection: A Novel Clinical Variant of Paraviral Exanthems and a Novel Virus Association.
    Chuh A; Panzer R; Rosenthal AC; Proksch E; Kempf W; Zawar V; Fickenscher H; Fölster-Holst R
    Acta Derm Venereol; 2017 Mar; 97(3):354-357. PubMed ID: 27701670
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Anti-SARS-CoV-2 Spike Protein RBD Antibody Levels After Receiving a Second Dose of ChAdOx1 nCov-19 (AZD1222) Vaccine in Healthcare Workers: Lack of Association With Age, Sex, Obesity, and Adverse Reactions.
    Lee SW; Moon JY; Lee SK; Lee H; Moon S; Chung SJ; Yeo Y; Park TS; Park DW; Kim TH; Sohn JW; Yoon HJ; Kim SH
    Front Immunol; 2021; 12():779212. PubMed ID: 34899739
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial.
    Ramasamy MN; Minassian AM; Ewer KJ; Flaxman AL; Folegatti PM; Owens DR; Voysey M; Aley PK; Angus B; Babbage G; Belij-Rammerstorfer S; Berry L; Bibi S; Bittaye M; Cathie K; Chappell H; Charlton S; Cicconi P; Clutterbuck EA; Colin-Jones R; Dold C; Emary KRW; Fedosyuk S; Fuskova M; Gbesemete D; Green C; Hallis B; Hou MM; Jenkin D; Joe CCD; Kelly EJ; Kerridge S; Lawrie AM; Lelliott A; Lwin MN; Makinson R; Marchevsky NG; Mujadidi Y; Munro APS; Pacurar M; Plested E; Rand J; Rawlinson T; Rhead S; Robinson H; Ritchie AJ; Ross-Russell AL; Saich S; Singh N; Smith CC; Snape MD; Song R; Tarrant R; Themistocleous Y; Thomas KM; Villafana TL; Warren SC; Watson MEE; Douglas AD; Hill AVS; Lambe T; Gilbert SC; Faust SN; Pollard AJ;
    Lancet; 2021 Dec; 396(10267):1979-1993. PubMed ID: 33220855
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Pseudoangiomatosis].
    Jans SR; Bygum A
    Ugeskr Laeger; 2014 Aug; 176(32):. PubMed ID: 25292473
    [No Abstract]   [Full Text] [Related]  

  • 39. Kinetics of the Antibody Response to Boostering With Three Different Vaccines Against SARS-CoV-2.
    Markewitz R; Juhl D; Pauli D; Görg S; Junker R; Rupp J; Engel S; Steinhagen K; Herbst V; Zapf D; Krüger C; Brockmann C; Leypoldt F; Dargvainiene J; Schomburg B; Sharifzadeh S; Nejad LS; Wandinger KP; Ziemann M
    Front Immunol; 2022; 13():811020. PubMed ID: 35126395
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Eruptive pseudoangiomatosis: report of an adult case and unifying hypothesis of the pathogenesis of paediatric and adult cases.
    Chaniotakis I; Nomikos K; Gamvroulia C; Zioga A; Stergiopoulou C; Bassukas ID
    Dermatology; 2007; 215(1):59-62. PubMed ID: 17587841
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.